Zhongqiang Lin

No. 58 Zhongshan Road 2
Guangzhou, 510080, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Corrigendum to "Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients" [Journal of Neuroimmunology. 2024 Nov 15:396:578464].

Corrigendum to "Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients" [Journal of Neuroimmunology. 2024 Nov 15:396:578464].

Journal: Journal of neuroimmunology

Published: February 09, 2025

Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients.

Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients.

Journal: Journal of neuroimmunology

Published: April 18, 2024

Extraocular muscle volume on time-of-flight magnetic resonance angiography in patients with myasthenia gravis.

Extraocular muscle volume on time-of-flight magnetic resonance angiography in patients with myasthenia gravis.

Journal: Muscle & nerve

Published: November 08, 2023

Long-term efficacy and safety of leflunomide combined with low-dose prednisone in treatment of myasthenia gravis: a retrospective study.

Long-term efficacy and safety of leflunomide combined with low-dose prednisone in treatment of myasthenia gravis: a retrospective study.

Journal: Acta neurologica Belgica

Published: March 03, 2023

Is myasthenia gravis a contraindication for botulinum toxin?

Is myasthenia gravis a contraindication for botulinum toxin?

Journal: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia

Published: July 21, 2021

Leflunomide ameliorates experimental autoimmune myasthenia gravis by regulating humoral and cellular immune responses.

Leflunomide ameliorates experimental autoimmune myasthenia gravis by regulating humoral and cellular immune responses.

Journal: International immunopharmacology

Published: January 12, 2021

Quantitative features and clinical significance of two subpopulations of AChR-specific CD4+ T cells in patients with myasthenia gravis.

Quantitative features and clinical significance of two subpopulations of AChR-specific CD4+ T cells in patients with myasthenia gravis.

Journal: Clinical immunology (Orlando, Fla.)

Published: January 18, 2020

Circulating Th1/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients.

Circulating Th1/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients.

Journal: Clinical immunology (Orlando, Fla.)

Published: December 25, 2019

AChR myasthenia gravis switching to MuSK or double antibody positive myasthenia gravis in two children and literature review.

AChR myasthenia gravis switching to MuSK or double antibody positive myasthenia gravis in two children and literature review.

Journal: Neuromuscular disorders : NMD

Published: July 10, 2019

Hospital and healthcare insurance system record-based epidemiological study of myasthenia gravis in southern and northern China.

Hospital and healthcare insurance system record-based epidemiological study of myasthenia gravis in southern and northern China.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: April 17, 2019

Imbalance of the two main circulating dendritic cell subsets in patients with myasthenia gravis.

Imbalance of the two main circulating dendritic cell subsets in patients with myasthenia gravis.

Journal: Clinical immunology (Orlando, Fla.)

Published: June 18, 2018

Showing 1-11 of 11

Last Updated: 09/26/2026